THE TALK: Gastrointestinal Cancers A Review of Data from the ESMO 2021 Virtual Meeting - Episode 4

ESMO 2021 Updates in Gastric Cancer and Colorectal Cancer

, , ,

Sam Klempner, MD; Daniel H. Ahn, DO; Nataliya V. Uboha, MD, PhD; and Manish A. Shah, MD, FASCO, review recent updates in second-line gastric cancer, CAR T-cell therapy in solid tumors, and colorectal cancer presented at ESMO 2021.

Data from the following clinical trials are discussed:

  • 1382P - Phase 1b/2 open-label, randomized evaluation of second-line atezolizumab (atezo) + linagliptin (lina) vs ramucirumab (ram) + paclitaxel (pac) in MORPHEUS-gastric cancer (MORPHEUS)
  • 1372O - CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system
  • LBA6 - KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation KRYSTAL-1